AstraZeneca drug fails in lung cancer trial
9th Aug 2016 07:13
(ShareCast News) - Pharmaceutical giant AstraZeneca announced results from the Phase III SELECT-1 trial of the MEK 1/2 inhibitor, selumetinib on Tuesday, in combination with docetaxel chemotherapy, as second-line treatment in patients with KRAS mutation-positive locally-advanced or metastatic non-sm
Read moreThursday broker round-up
4th Aug 2016 11:59
(ShareCast News) - Next: Goldman Sachs reiterates sell with a target price of 4800p. Standard Chartered: JP Morgan maintains overweight with a 800p target. Shire: JP Morgan reiterates overweight with a 6300p target. Genus: HSBC stays at buy with a 2200p target. Nichols: UBS keeps at buy with a ta
Read moreSector movers: Oil-related sectors retreat as Aerospace & Defence flies
28th Jul 2016 16:42
(ShareCast News) - FTSE indices were mixed heading towards the closing bell on Thursday, with the blue-chip index helped south by oil stocks undermined by crude's weakness and Royal Dutch Shell's second-quarter shocker. "An unsurprisingly indecisive session in Europe has seen the likes of the FTSE l
Read moreAstraZeneca earnings see serious fall in first half
28th Jul 2016 08:38
(ShareCast News) - Drug giant AstraZeneca posted its first half results on Thursday, with total revenue down by 3% at constant exchange rates to $11.718bn as expected, reflecting a 2% decline in product sales to $11.034bn.. The FTSE 100 firm said this was driven by patent expiries, in particular Cre
Read moreAstraZeneca celebrates success in latest Tagrisso trial
18th Jul 2016 07:06
(ShareCast News) - AstraZeneca announced on Monday that the Phase III AURA3 trial has met its primary endpoint, demonstrating superior progression-free survival (PFS) compared to standard platinum-based doublet chemotherapy. The FTSE 100 pharmaceutical giant said the AURA3 randomised trial assessed
Read moreAstraZeneca reaches settlement with Sandoz over fulvestrant
13th Jul 2016 07:23
(ShareCast News) - Pharmaceutical giant AstraZeneca announced on Wednesday that it has entered into an agreement with Sandoz and its affiliates to resolve litigation relating to Faslodex (fulvestrant). The FTSE 100 firm said the litigation related to Sandoz's generic fulvestrant product, for which i
Read moreAstraZeneca mulling making a bid for America´s Medivation
11th Jul 2016 08:23
(ShareCast News) - AstraZeneca was mulling joining the fray for US drug outfit Medivation, according to a report published over the weekend. Just at the start of last week the American company, which markets a blockbuster treatment for prostate cancer, saw off another hostile take-over attempt from
Read moreSunday newspaper round-up: AstraZeneca, Asda, Italy
10th Jul 2016 16:58
(ShareCast News) - AstraZeneca is considering tabling a last-minute bid for a $10bn (£7.7bn) American cancer drug developer, which has become a target for some of the world's largest pharmaceutical companies. Medivation, which last week opened its books to Pfizer and Sanofi, is still courting other
Read moreSector movers: House builders and banks rally
8th Jul 2016 18:37
(ShareCast News) - House builders, banks topped the blue-chip winners' ladder at close of play on Friday, having last week and this suffered under the shadow of Britain's non-binding vote to quit the EU. Taylor Wimpey, Berkeley Group, Barratt Developments and Persimmon sprinted higher with gains of
Read moreAstraZeneca signs up to $1bn deal with LEO Pharma
1st Jul 2016 07:19
(ShareCast News) - Pharmaceutical giant AstraZeneca announced on Friday it has entered into agreements to support its strategic focus on three main therapy areas - respiratory, inflammation and autoimmunity; cardiovascular and metabolic disease; and oncology. The FTSE 100 firm said the agreements in
Read moreAstrazeneca wins approval for new antibiotic in fight against drug resistance
28th Jun 2016 07:08
(ShareCast News) - AstraZeneca has won European regulatory approval for Zavicefta, a combination antibiotic developed in response to the increasingly urgent need for new drugs to treat serious infections that are becoming increasingly resistant to antibiotics. Zavicefta, a combination of ceftazidime
Read moreSunday share tips: EasyJet, Randgold, Imperial Brands, AstraZeneca
26th Jun 2016 14:03
(ShareCast News) - Sell EasyJet shares due to the likely turbulence sparked by the Brexit vote, said the Sunday Times' Inside the City column. The budget airline was created by Stelios Haji-Ioannou in the wake of the 1992 European Union Treaty on Open Skies, one of the supposedly rare bits of Brusse
Read moreUS authorities recommend against AstraZeneca flu vaccine
23rd Jun 2016 07:32
(ShareCast News) - Pharmaceutical giant AstraZeneca confirmed disappointing news to investors on Thursday, with updated guidance from US regulators recommending against its FluMist Quadrivalent influenza vaccine. The FTSE 100 firm said the updated guidance from the Advisory Committee on Immunization
Read moreLeave vote would have limited impact on FTSE, says SpreadCo analyst
21st Jun 2016 13:12
(ShareCast News) - Although consensus is that the FTSE 100 will rally if voters in the UK opt to remain in the European Union on Thursday and sell off on a Leave vote, the overall impact of an exit on London stocks may be limited, said SpreadCo analyst David Morrison. "The damage to the FTSE100 as a
Read moreBroker tips: Imperial Brands, Poundland, Astrazeneca
17th Jun 2016 12:06
(ShareCast News) - RBC Capital Markets upgraded Imperial Brands to 'sector perform' from 'underperform' and lifted the price target to 3,700p from 2,900p. The Canadian bank said Imperial's expected full-year 2017 dividend yield of 4.9% is the highest in its coverage and particularly attractive in th
Read more